ArticleFrontiers in microbiology2022
Rapid Identification of
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Discrimination betweenOne health (Amsterdam, Netherlands) · 2026Article
- Non-tuberculous mycobacteria in cattle: Distribution, antimicrobial resistance and zoonotic implications in Tamil Nadu, India.Veterinary research communications · 2026Article
- Article
- Snapshot based on whole-genome sequencing revealing the species and antimicrobial susceptibility profiles of Mycobacterium tuberculosis complex recovered at a major tertiary care center in Lebanon.BMC infectious diseases · 2026Article
- Advancing the fight against tuberculosis: integrating innovation and public health in diagnosis, treatment, vaccine development, and implementation science.Frontiers in medicine · 2025Review
- A comparative study using Xpert MTB/RIF and culture methods evaluates MassARRAY technology for rapid detection ofFrontiers in cellular and infection microbiology · 2025Article
- Diagnostic performance of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in bronchoalveolar lavage fluid for pulmonary tuberculosis in HIV-infected patients.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- Article
- Detection of Mycobacterium angelicum in Human Urinary Tract, French Polynesia.Emerging infectious diseases · 2023Article
- Improved MALDI-TOF MS Identification ofMicroorganisms · 2023Article
- Evolution of tuberculosis diagnostics: From molecular strategies to nanodiagnostics.Tuberculosis (Edinburgh, Scotland) · 2023Review
- TheAccess microbiology · 2023Article
- How MALDI-TOF Mass Spectrometry Technology Contributes to Microbial Infection Control in Healthcare Settings.Vaccines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycobacteria that form the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.